Charlotte Videbaek
Directeur/Membre du Conseil chez CESSATECH A/S
Provenance du réseau au premier degré de Charlotte Videbaek
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 16 | |
| Public Company | Pharmaceuticals: Major | 12 | |
Neurokey A/S
 Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.
10
| Extinct | Pharmaceuticals: Major | 10 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Charlotte Videbaek via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| University of Copenhagen | College/University | Graduate Degree Doctorate Degree Masters Business Admin Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree Graduate Degree | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Public Communications Contact Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
| University of Southern Denmark | College/University | Graduate Degree Masters Business Admin Undergraduate Degree Doctorate Degree Graduate Degree | |
| University of Aarhus | College/University | Graduate Degree Corporate Officer/Principal Graduate Degree Graduate Degree | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | President Corporate Officer/Principal Corporate Officer/Principal | |
| Danmarks Farmaceutiske Universitet | College/University | Graduate Degree Doctorate Degree Undergraduate Degree | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Sales & Marketing | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Undergraduate Degree | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
Contera Pharma ApS
 Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Director/Board Member | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor | |
Azanta Danmark A/S
 Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| GENMAB A/S | Pharmaceuticals: Major | Director/Board Member Investor Relations Contact | |
Bok Holding A/S
 Bok Holding A/S BiotechnologyHealth Technology Bok Holding A/S is a holding company that operates as a biotechnology company that researches and develops cancer treatment solutions. It develops the ZAS platform technology which efficiently enhances the effect of current anti-cancer drugs and reduces toxicity. The firm employs molecular techniques commonly known as molecular breeding or directed enzyme evolution which can activate anti-cancer drugs. The company was founded by Zoran Gojkovic on November 22, 2001 and is headquartered in Gentofte, Denmark. | Biotechnology | Chairman Director/Board Member | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Public Communications Contact Corporate Officer/Principal | |
SEED Capital Management I/S
 SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor Private Equity Investor | |
Rigshospitalet
 Rigshospitalet Hospital/Nursing ManagementHealth Services Rigshospitalet is a highly specialized hospital in Denmark that ensures all patients in Denmark have a treatment offer, no matter how rare or complicated their illness is. The hospital is located on Blegdamsvej and in Glostrup. Rigshospitalet prioritizes research and achieves and disseminates results through extensive national and international cooperation. The hospital has subsidiaries in Denmark. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
Thesan Pharmaceuticals, Inc.
 Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
Allarity Therapeutics A/S
 Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
| BOLT BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Acesion Pharma ApS
 Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| GN STORE NORD A/S | Telecommunications Equipment | Chairman Corporate Officer/Principal | |
| ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| ALK-ABELLÓ A/S | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Outpost Medicine, Inc.
 Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
MetaCure (USA), Inc.
 MetaCure (USA), Inc. Pharmaceuticals: MajorHealth Technology MetaCure (USA), Inc. engages in the development and commercialization of invasive treatment for diabetes. The company was founded by Shlomo Ben-Haim in 2003 and is headquartered in Orangeburg, NY. | Pharmaceuticals: Major | Director/Board Member | |
Chempilots A/S
 Chempilots A/S Miscellaneous ManufacturingProducer Manufacturing Part of Biocoat, Inc., Chempilots A/S is a Danish company that specializes in developing and providing custom polymers using state-of-the-art technology. The company is based in Farum, Denmark. The company offers a range of pre-specified products to signify their capabilities and give customers a starting point for selection. Chempilots specializes in poly(ortho esters) (poe), which belong to a class of degradable polymeric materials and were initially developed for drug delivery applications. Chempilots was acquired by Biocoat, Inc. on July 11, 2023. | Miscellaneous Manufacturing | Director/Board Member | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chief Executive Officer | |
Cellectricon AB
 Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
PricewaterhouseCoopers (Denmark)
 PricewaterhouseCoopers (Denmark) Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., PricewaterhouseCoopers (Denmark) is a company based in Hellerup, Denmark. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| ACOUSORT AB | Medical Distributors | Chairman | |
| SLS Invest ApS | Chief Investment Officer | ||
| Zealand Business College | College/University | Undergraduate Degree | |
Nordic Eye Management ApS
 Nordic Eye Management ApS Financial ConglomeratesFinance Part of Nordic Eye Invest ApS, Nordic Eye Management ApS is an international venture capital firm based in Copenhagen, Denmark. The Danish company's brand promise is to spot, add, and exit, creating high value through a unique network, energetic and passionate collaboration, and an imaginative and commercial mindset. Nordic Eye has a strong personal network throughout the world, especially in the core markets. The CEO of the company is Martin Olin. | Financial Conglomerates | Chief Executive Officer | |
| BERGENBIO ASA | Pharmaceuticals: Major | Chief Executive Officer | |
Nordic Eye Invest ApS
 Nordic Eye Invest ApS Investment ManagersFinance Nordic Eye Invest ApS (Nordic Eye) is an independent Danish venture capital firm which was founded in 2016. Nordic Eye is fully-owned by its partners, and has offices in Copenhagen, Denmark, and Los Angeles, California. | Investment Managers | Corporate Officer/Principal | |
RSP Systems A/S
 RSP Systems A/S Medical SpecialtiesHealth Technology RSP Systems A/S provides non-invasive solutions for sugar and insulin blood level measurements. Its products are used to make measurements of molecules in terms of identification and quantities. The company was founded by Olav Storm Kjestrup, Stefan Banke, and Morten Henneberg in May 2006 and is headquartered in Odense, Denmark | Medical Specialties | Chairman |
Statistiques
Internationale
| Danemark | 40 |
| Etats-Unis | 7 |
| Suède | 4 |
| Norvège | 2 |
Sectorielle
| Health Technology | 25 |
| Finance | 9 |
| Consumer Services | 8 |
| Electronic Technology | 3 |
| Commercial Services | 3 |
Opérationnelle
| Director/Board Member | 164 |
| Corporate Officer/Principal | 76 |
| Chairman | 71 |
| Independent Dir/Board Member | 30 |
| Chief Executive Officer | 25 |
Relations les plus connectées
| Insiders | |
|---|---|
| Flemming Bent Lindeløv | 46 |
| Marie-Laure Jeanne Antoinette Pochon | 36 |
| Peter Bisgaard | 28 |
| Peter Moldt | 25 |
| Martin Olin | 25 |
| Per Wold-Olsen | 24 |
| Frank Knudsen | 21 |
| Carsten Schou | 20 |
| Egil Bodd | 18 |
| Ulla Hald Buhl | 12 |
| Anders Götzsche | 11 |
| Finn Eggert Sørensen | 10 |
| Flemming Steen Jensen | 10 |
| Hans Henrik Munch-Jensen | 10 |
| Adam Sinding Steensberg | 9 |
- Bourse
- Insiders
- Charlotte Videbaek
- Connexions Sociétés
